Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07119333

Classroom Air Purifiers for Reducing School Absence

Background

Respiratory infections like influenza and SARS-CoV-2 pose significant global health risks due to their high transmissibility and severity. SARS-CoV-2 has caused over 7 million deaths worldwide, and the Lancet Commission estimates a >20% chance of a similar respiratory virus pandemic within a decade. Schools, often poorly ventilated, are high-risk settings for transmission. While COVID-19 school closures may have reduced transmission, they likely caused learning loss, mental health issues, and increased burdens on parents and caregivers. Air purifiers with HEPA filters may offer a non-disruptive mitigation strategy, but the evidence to support their effectiveness in reducing viral transmission is weak. This protocol describes a cluster-randomised, parallel, two-arm, group sequential superiority trial with an interim analysis-to allow early stopping for efficacy or futility-to estimate the effect of portable air purifiers with HEPA filters in primary school classrooms on student absenteeism.

Research Questions

The primary question is whether installing and operating air purifiers with HEPA-filters (intervention) reduce student absenteeism (primary outcome) compared to sham air purifiers (control). Secondary questions examine whether the intervention reduces teacher absenteeism due to respiratory infections, rate and 12-week risk of self-reported respiratory infections among teachers, and teachers' perceived air quality compared to sham air purifiers. If the trial estimates a statistically significant effect for the primary outcome, a cost-consequence analysis will evaluate the direct and indirect costs associating with operating air purifiers against the potential benefits of reduced student and teacher absenteeism. A process evaluation will explore mechanisms of effect.

Methods and Analysis

This group sequential trial will randomize schools (clusters) 1:1 to intervention or control arms in two stages: winter 2025/2026 (N = 32 schools; ~736 students) and winter 2026/2027 (N = 30 schools; ~690 students). Eligible schools must have classrooms suitable for portable air purifiers, >10 students in grades 5-7 (typically aged 10-13 years), and principal consent. Intervention and control classrooms will each receive two portable air purifiers with HEPA-filters operating at a performance equivalent to 3.0 and 0.3 air changes per hour, respectively, with control purifiers acting as shams.

Outcomes will be measured during and at the end of a 12-week period. The primary outcome is student absenteeism, measured as full child-days of absence aggregated at the class level. An interim analysis is planned at the end of the first stage, with error-spending O'Brien-Fleming stopping boundaries that are binding for efficacy and nonbinding for futility.

The primary estimand is the marginal incidence rate ratio of student absences, estimated using generalized estimating equations with a negative binomial model to account for overdispersion. Prespecified stopping boundaries will determine stopping, with efficacy boundaries being binding. Treatment effects will be estimated using cluster-bootstrapped confidence intervals adjusted to provide strong control on overall type I and II error probabilities, and a bias correction will be applied if the trial is stopped early for efficacy. All analyses will follow the intention-to-treat principle.

Ethics and Dissemination

The trial has been approved by the Regional Committees for Medical and Health Research Ethics and the National Research Ethics Committee. Results will be disseminated to stakeholders, participants and the public through peer-reviewed journals, scientific meetings and social media.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

10 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Norwegian Institute of Public Health

Oslo, 0213, Norway

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

There are two general trial populations. The first population is primary school children in Norway. Primary school children in primary schools meeting the following criteria will be eligible:

  • Schools with more than 10 students in either 5th, 6th, or 7th grade (typically aged 10-13 years).
  • Schools with at least one classroom of sufficient dimensions to accommodate the installation of two portable air purifiers.
  • The school principal accepts the installation of air purifiers in at least one classroom in the 5th, 6th, or 7th grade that meets the first two inclusion criteria.

For logistical and administrative reasons, the investigators will try to limit the sampling frame to schools in municipalities located close our offices in Oslo. These municipalities include several large towns with populations of around 30 000 to 100 000 people, as well as sparsely populated rural areas, and are therefore reasonably representative of Norway and many other countries. The investigators will enlarge the sampling frame as necessary.

The second population is teachers at primary schools in Norway. Teachers meeting the following criteria will be eligible.

  • Be the main class teacher of one or more of the classrooms included in the trial.
  • Provide informed consent.

Treatment and study plan

Air purifiers

Device

Air purifiers

Sham air purifiers

Device

Sham air purifiers

Primary outcomes

  1. Student absenteeism

    Time frame: From enrollment to the end of intervention at 12 weeks

    The primary outcome is the number of student-days of absence per classroom, measured each week. The investigators will define a student day of absence as a day for which a student is absent for the entire day. The investigators will not distinguish between the specific students who are absent (i.e., two days of absence will be counted for one student who is absent on two days, and for two students absent for one day each).

Secondary outcomes

  1. Self-reported absence due to respiratory infections among teachers

    Time frame: From enrollment to the end of intervention at 12 weeks

    The investigators will measure the number of teacher-days of work absence (sick leave) due to self-reported respiratory infection each week. The investigators will ask teachers "Did you experience symptoms of a cold, COVID-19 or the flu last week?". Teachers who answer "Yes" to this question, will be asked to specify the symptoms they experienced (sneezing, nasal obstruction, nasal discharge, sore throath, cough, headache, fever or general discomfort) and rate each symptom from 0 to 3, where 0 = absent, 1 = mild, 2 = moderate, 3 = severe, in accordance with the Jackson index. They will then report the number of days they experienced these symptoms (ranging from 1 to 7 days), before answering "How many days were you absent from work last week due to respiratory infection?"; their response to this question will be used to measure number of days of absence. A count of zero days will be assigned to teachers answering "No" to the first question.

  2. Incidence of self-reported respiratory symptoms consistent with respiratory infections among teachers

    Time frame: From enrollment to the end of the intervention at 12 weeks

    The investigators will assess incidents of respiratory symptoms consistent with respiratory infections among teachers using self-reported data collected weekly. The investigators define an incident as a period during which a teacher reports symptoms for at least two consecutive calendar days, preceded and followed by at least 7 symptom-free calendar days. The investigators define symptoms of respiratory infection as meeting all four of the following criteria:

    • Answering "yes" to the question "Did you experience symptoms of a cold, COVID-19 or the flu last week?".
    • Reporting at least one of the following symptoms: nasal obstruction (plugged or congested), nasal discharge (runny nose), sneezing or sore throat, in the last week;
    • Scoring at least four points on the Jackson scale (as assessed for the preceding week);
    • Reporting that they have experienced at least one of the reported symptoms for at least two consecutive days in the last week.
  3. Teachers reporting respiratory infections

    Time frame: From enrollment to the end of the intervention at 12 weeks

    The investigators will assess respiratory infection as a dichotomous outcome for each teacher, based on whether they meet the case definition at any point during the 12-week follow-up.

  4. Teacher perceptions of air quality in classrooms

    Time frame: From enrollment to the end of the intervention at 12 weeks

    The investigators will assess teachers' perceptions of classroom air quality at the end of follow-up using the MM040 questionnaire: teachers will report whether they have experienced drafts, high room temperature, low room temperature, fluctuating room temperature, stuffy or "bad" air, dry air, unpleasant odours, noise, or dust in the air during follow-up. The response options will be: "Yes, often (every week)," "Yes, occasionally," or "No, never".

  5. Adverse events

    Time frame: From enrollment to the end of the intervention at 12 weeks

    The investigators define an adverse event as any significant disruption to lessons, or any accident or injury, that is attributable to the intervention or control. The investigators will instruct school principals and teachers to report such events.

Sponsors and collaborators

Lead sponsor

Norwegian Institute of Public Health

Other Gov

Registry information

Official study title

Classroom Air Purifiers for Reducing School Absence: Protocol for a Cluster-randomized, Parallel, Two-arm, Group Sequential Superiority Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 13, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.